Aprea Therapeutics APRE

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
-$0.15 (-6.05%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0

Relative Strength Index (RSI)

- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

- The RSI is calculated using the following formula:

RSI = 100 - (100 / (1 + RS))

Where RS is the ratio of the average gains to the average losses over a specified period.

- The default time period used is 14 days.

- RSI values range between 0 and 100.

RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

About

Business overview of Aprea Therapeutics (APRE)
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.

Key Insights

Critical company metrics and information

  • Latest Closing Price

    $2.33

  • Market Cap

    $12.66 Million

  • Price-Earnings Ratio

    -0.83

  • Total Outstanding Shares

    5.44 Million Shares

  • Total Employees

    7

  • Dividend

    No dividend

  • IPO Date

    October 3, 2019

  • SIC Description

    Pharmaceutical Preparations

  • Primary Exchange

    NASDAQ

  • Type

    Common Stock

  • Headquarters

    3805 old easton road, Doylestown, PA, 18902

  • Homepage

    https://www.aprea.com

Historical Stock Splits

If you bought 10,000,000 shares of APRE before September 13, 2011, you'd have 1 share today.
Execution DateSplit Amount
February 13, 20231-for-20 (Reverse Split)
December 27, 20181-for-1000 (Reverse Split)
September 13, 20111-for-500 (Reverse Split)

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Operating Activities, Continuing$-13.79 Million
Net Cash Flow From Operating Activities$-13.79 Million
Net Cash Flow From Financing Activities, Continuing$14.69 Million
Net Cash Flow$879,390
Net Cash Flow From Financing Activities$14.69 Million
Net Cash Flow From Investing Activities, Continuing$-22,628

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Income/Loss Available To Common Stockholders, Basic$-13.51 Million
Net Income/Loss$-13.51 Million
Net Income/Loss Attributable To Parent$-13.51 Million
Income/Loss From Continuing Operations Before Tax$-13.51 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0
Diluted Earnings Per Share$-2.80

Comprehensive Income

October 1, 2023 to September 30, 2024
MetricValue
Comprehensive Income/Loss$-13.46 Million
Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
Other Comprehensive Income/Loss$-3.74 Million
Comprehensive Income/Loss Attributable To Parent$-13.48 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Other Current Liabilities$1.81 Million
Liabilities$4.95 Million
Fixed Assets$86,950
Wages$673,322
Current Assets$26.48 Million
Liabilities And Equity$26.89 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends

Recent Headlines From The Web

Latest news, press releases, and media coverage about APRE from trusted financial sources
    All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

    ⓒ 2025 Financhle. All Rights Reserved.